N-Nitrosamine directed stereoselective O-

glycosylation reactions of 2-amino thioglycosides

with NIS-TfOH under mild reaction condtions

5.1 Introduction

N-Nitroso compounds are found in a wide range of food items and cosmetics [1]. Among the different classes of *N*-Nitroso compounds, *N*-Nitrosamines received particular attention due to their carcinogenic and mutagenic properties [2]. Moreover, the compounds bearing the nitrosamine group display various biological properties including anticancer and antimicrobial activities (**Figure 5.1**) [3]. On the other hand, *N*-Nitrosamines are used as synthetic intermediates in the preparation of hydrazines, sydnones, aryl *C*-Nitroso compounds, etc [4]. Transition-metal catalyzed directing groups assisted *C*-H bond activation reactions and received great interest in modern organic synthesis [5]. In this context, the *N*-Nitrosamine functional group has emerged as a traceless directing group for the activation of ortho *C*-H bonds in aryl rings [6]. In principle, the *N*-Nitrosamine group directs the metal insertion at the *ortho*-carbon of the aryl ring that facilitates the regioselective functionalization reactions in a simple and efficient manner (**Scheme 5.1**).






Figure 5.1. Biologically relevant N-Nitrosamines



Aryl-N-Nitroso




Carbohydrates are important biomolecules that play key roles in human health and diseases. Hence, the synthesis of structurally well-defined oligosaccharides is crucial for understanding the appropriate role of carbohydrates in biological systems [7]. Glycosylation reaction is the key step in the oligosaccharides assembly by which glycosides or glycoconjugates are generated with required stereochemistry at the anomeric position [8]. To achieve a high stereoselectivity in glycosylation reactions, various types of glycosyl donors and different activation strategies have been demonstrated in the literature [8, 9]. In general, the presence of a participating group in the C-2 position of the donor provides 1, 2-trans glycosides with excellent stereoselectivity. In particular, acyl groups (e.g. acetyl, benzoyl, etc.) were predominantly used as the directing groups for the glycosyl donors possessing hydroxyl group at the C-2 position [8, 9]. In the case of glycosyl donors with primary amines at the C-2 position, troc and phthalimide groups were used as directing groups [10]. However, participating groups for the glycosyl donors bearing secondary amines at the C-2 position is not well studied. In the past few years, our group research is focused on the chemistry of N-Nitrosamines and we have explored the synthesis and applications of N-Nitrosamines in various transformations [11]. In addition, our group also contributed to the synthesis of O-Glycosides and C-Glycosides, uronic acids, and photolabile protecting groups, etc [12]. With this background, here we have aimed to explore the N-Nitrosamine as the directing group in the glycosylation reactions to achieve 1, 2-trans glycosides (Scheme 5.2).



Scheme 5.2. *N*-Nitrosamine as the directing group in the stereoselective glycosylation reactions.


5.2 Results and Discussion

In the beginning, synthesis of benzyl-protected glucose and galactose *N*-Nitroso thioglycosides **1a** and **2a**, respectively was achieved as shown in **Scheme 5.3 and 5.4**. Synthesis of **1a** was achieved in 9 steps from *N*-Acetyl glucose **1**. Initially, compound **1** was converted into *O*-Acetyl β -Thioglycoside **2** *via* acetylation followed by thioglycosylation reactions. Subsequently, the compound **2** was converted into *O*-Benzyl β -Thioglycoside **3** through deacetylation followed by *O*-Benzylation reactions [13]. Further, the conversion of **3** to the free amine **5** (i.e. *N*-Deacetylation) was attempted with alkali hydroxides (NaOH and KOH) from room temperature to reflux conditions. However, these reactions gave a very low yield of the free amine **5**. Hence, alternative routes of *N*-Deacetylation reaction were investigated. Towards this end, *N*-Deacetylation was achieved in excellent yield via *N*-Boc protection followed by *N*-Deacetylation which gave *N*-Boc Thioglycoside **4** in good yield. The compound **4** was easily converted into free amine **5** using TFA in DCM at 0°C-RT. Further, the compound **5** was *N*-Benzylated to obtain **6** which was subsequently converted into *N*-Nitroso β -Thioglucoside **1a** using tert-butyl nitrite in dichloromethane.




Scheme 5.3. Synthesis of benzyl-protected glucose N-Nitroso thioglycosides 1a

On the other hand, the compound **1b** was prepared from *O*-Acetyl D-galactal (**7**) in seven steps. Initially, the galactal **7** was converted into 2-Azido O-acetyl thioglycoside **8** via chloro-azidation followed by thioglycosylation reactions [14]. Further, *O*-Deacetylation and benzylation reactions gave the azido compound **9**. Further, the reduction of the azide group with Zn-acetic acid followed by *N*-Benzylation with benzyl bromide provided compound **10**. Further, the amino sugar **10** is converted into desired *N*-Nitroso β -Thiogalactoside **1b** using *tert*-butyl nitrite in dichloromethane. After the preparation of *N*-Nitroso donors **1a** and **1b**, the glycosylation reactions were investigated.



Scheme 5.4. Synthesis of benzyl-protected galactose N-Nitroso thioglycosides 2a.

At the outset, optimization of the glycosylation conditions was performed by choosing *N*-Nitroso thioglycoside **1a** and butanol **2a** as model substrates (**Table 5.1**). The glycosylation reaction was performed in dichloromethane at 0 °C using NIS/TMSOTf, NIS/BF₃.OEt₂ and NIS/TfOH as activating agents. To our delight, these reactions provided the desired product **3a** in 45-71% yield with high stereoselectivity (α : β =>20:1). The stereochemistry at the anomeric position was confirmed by the 2D NMR spectrum like COSY and HSQC. The NIS/TfOH system was found to be better than other systems. Hence the activation was further performed under different temperatures. It was observed that the reaction proceeds with a better yield at -10 °C when compared with -30, 0, 10, and RT. Moreover, DCM was found to be the best solvent for the glycosylation reaction.




OBn	(2 a) OH	OBn
BnO SPh - N-NO	"Conditions"	BnO BnO NNO
Bn	4A°, MS	Bn NO
1a		3a


Entry	Activation reagents	Solvent	Temperature	Time	Yield ^b (%)
	(equiv.)		(°C)		
1	NIS/TMSOTf	DCM	0	2h	61
	(1/0.1)				
2	NIS/BF ₃ .OEt ₂	DCM	0	6h	45
	(1/0.1)				
3	NIS/TfOH	DCM	0	5h	71
	(1/0.1)				
4	NIS/TfOH	DCM	-30	4h	74
	(1/0.1)				
5	NIS/TfOH	DCM	-10	3h	75
	(1.2/0.1)				
6	NIS/TfOH	DCM	10	6h	69
	(1.2/0.1)				
7	NIS/TfOH	DCM	RT	6h	51
	(1.2/0.1)				
8	NIS/TfOH	CH ₃ CN	-10	4h	57
	(1.2/0.1)				
9	NIS/TfOH	Et ₂ O	-10	4h	65
	(1.2/0.1)				

^a**Reaction condition:** Substrate **1a** (0.1 mmol), alcohol (3 equiv.), NIS (1.2 equiv.), TfOH (0.1 equiv.), dry DCM (3ml). ^bIsolated yield.

After establishing the optimized conditions glycosylation of different non-sugar acceptors with *N*-Nitroso thioglycoside **1a** was investigated. Glycosylation of primary alcohols such


as octanol and iso-amyl alcohol with **1a** gave the desired glycosides **3b** and **3c** in 76-80% yields. On the other hand, secondary alcohols such as isopropanol, cyclohexanol, menthol, and sterol also gave the desired glycosides in 80-81% yield with excellent stereoselectivity. Further to our delight, the tert-alcohols such as tert-butanol and adamentanol gave the desired products in 84-64% yields. Further, various functionalized benzyl alcohols were subjected to glycosylation with **1a**. These reactions gave the corresponding *O*-glycosides **3j-3k** in good to excellent yields, irrespective of the functional groups present in the benzyl alcohols.






^a**Reaction condition:** Substrate **1a** (0.1 mmol), alcohol (3 equiv.), NIS (1.2 equiv.), TfOH (0.1 equiv.), dry DCM (3ml). ^bIsolated yield.

Further, we have tried the glycosylation reaction of various sugar acceptors with N-Nitroso thioglycoside **1a.** For this investigation, different sugar acceptors with primary and secondary alcohols were prepared and subjected to the glycosylation reaction under optimized conditions. α -Methyl glucoside bearing benzyl and benzoyl protecting groups and primary alcohol gave the desired product 3p and 3q were achieved in good yields. Similarly, secondary alcohols acceptors such as α -Methyl glucoside bearing benzyl and benzoyl protecting groups 3p and 3q were achieved in good yields. Similar to glucose and mannose, galactose acceptor also participated in the glycosylation reaction and provided the desired product in excellent yield.






^a**Reaction condition**: Substrate **1a** (0.1 mmol), alcohol (1.2 equiv.), NIS (1.2 equiv.), TfOH (0.1 equiv.), dry DCM (3ml). ^bIsolated yield.

Further, we have explored the glycosylation of *N*-Nitroso thioglycoside 2a galactosamine with glycosylation reaction with primary and secondary alcohols. To our delight, these reactions gave the desired products 4a and 4b in good yields (72-77%).






^a**Reaction condition: 1b** (0.1 mmol), alcohol (3 equiv.), NIS (1.2 equiv.), TfOH (0.1 equiv.), dry DCM (3ml).^bIsolated yield.

5.3 Proposed mechanism of the reaction

A proposed mechanism of the reactions was shown in **Scheme 5.1**. Activation of thioglycoside with NIS/TfOH provides the oxonium ion intermediate **A**. Simultaneously, the *N*-Nitrosamine undergoes delocalization and provides anchimeric assistance to form the intermediate **B** and allows the acceptor to attack from the top phase and provides β -selective glycosides.




5.4 Conclusions:


The *N*-Nitrosamine-directed stereoselective *O*-glycosylation reactions of 2-amino thioglycosides with various acceptors were demonstrated under mild reaction conditions. The reaction was activated by using NIS/TfOH system in dichloromethane at -10 °C. Various sugar and non-sugar acceptors were successfully glycosylated with different donors including 2-amino 1-thioglucoside and 2-amino 1-thioglactoside under optimized conditions. These reactions provided the desired β -glycosides in good to excellent yields in a short span of time.

5.5 Experimental Section

5.5.1 Synthesis of thio 3,4,6-tri-*O*-benzyl-2-(*tert*-butyloxycarbonylamino)-2-deoxy-β-D-glucopyranoside (4)




The solution of thio 2-(*N*-acetyl)-3,4,6-tri-*O*-benzyl-2-(*tert*-butyloxycarbonylamino)-2deoxy- β -D-glucopyranoside (700 mg, 1.0 mmol) and hydrazine hydrate(1.0 mL 20 eq.) in MeOH was stirred at room temperature for 1h. After the completion of the reaction, methanol was evaporated by a rotatory evaporator, and the residue was redissolved in dichloromethane. The organic layer was washed with a saturated solution of NaHCO₃ respectively, dried with anhydrous sodium sulfate, and concentrated to afford the crude product which was further purified by silica gel chromatography to obtain the product. 5.5.2 Synthesis of thio 2-amino-3,4,6-tri-*O*-benzyl-2-deoxy-β-D-glucopyranoside (5)




To the solution of thio 3,4,6-tri-*O*-benzyl-2-(*tert*-butyloxycarbonylamino)-2-deoxy- β -D-glucopyranoside (700 mg, 1.0 mmol) in dichloromethane, trifluoroacetic acid (1.0 mL, 12.0 eq.) was added and the resulting reaction mixture was stirred at room temperature for 30 minutes. After the completion of the reaction, the reaction mixture was evaporated by a rotatory evaporator and redissolved in dichloromethane. The organic layer was washed with 10% NaHCO₃ and water and concentrated on the obtained crude product which was further purified by silica gel column chromatography to obtain a pure product.

5.5.3 Synthesis of thio-2-*N*-benzyl amino-3, 4, 6-tri-*O*-benzyl-2-deoxy-β-Dglucopyranoside (6)




To the solution of thio 2-amino-3,4,6-tri-*O*-benzyl-2-deoxy- β -D-glucopyranoside (550 mg,1.0 mmol) in dry AcCN, benzyl bromide (186.0mml, 1.5eq.) was added then dropwise added triethylamine (196.0mml, 1.5eq.) and the resulting reaction mixture was stirred at room temperature overnight. After the completion of the reaction, the solvent was evaporated and redissolved in DCM the organic layer washed with aq. NaHCO₃ and water and brine solution and dried (Na₂SO₄) concentrated on the obtained crude product which was further purified by column chromatography to obtain a pure product.

5.5.4 Synthesis of thio-2-*N*-benzyl-*N*-Nitroso-3, 4, 6-tri-*O*-benzyl-2-deoxy-β-Dglucopyranoside (1a)



To the solution of thio 2-*N*-benzyl amine-3, 4, 6-tri-O-benzyl-2-deoxy- β -D-glucopyranoside (650mg, 1.0 mmol) in dry DCM, TBN (367.0 mml, 3.0eq.) was added and stirred at 40°C for 2h. After completion of the reaction, the solvent evaporates and redissolves in DCM and washed with water and brine solution, and dried with (Na₂SO₄) concentrated and further purified using silica gel chromatography and obtaining the desired product.

5.5.5 Synthesis of thio-2-*N*-benzyl-*N*-Nitroso-3, 4, 6-tri-*O*-benzyl-2-deoxy-β-D-galactopyranoside (1b)



To the solution of thio 2-*N*-benzyl amine-3, 4, 6-tri-O-benzyl-2-deoxy- β -D-galactopyranoside (650.0 mg, 1.0 mmol) in dry DCM, TBN (367.0 mml, 3eq.) was added and stirred at RT for 5h. After completion of the reaction, the solvent evaporates and redissolves in DCM and washed with water and brine solution, and dried with (Na₂SO₄)

concentrated and further purified using silica gel chromatography and obtaining the desired product.

5.5.6 General Procedure for Glycosylation

Donor (1 equiv.) and acceptor (3 equiv. for non-sugar and 1.2 equiv. for carbohydrate alcohol) were stirred in freshly dried DCM with 4 A° MS in (4-5 ml) at -10 °C. Take donor and NIS (1.2 equiv.) and keep staring for 5 min. and then add acceptor, finally add activator TfOH (0.1 equiv.) and keep for stare. The reaction completely confirms by TLC. After the complete reaction is quenched by triethylamine with a few drops, for diluting the reaction add DCM (10-15 ml) and washed with water and NaHCO₃ with brine solution, dry over Na₂SO₄, filter, and concentrated. The residue was purified by column chromatography (hexane/ ethyl acetate) using silica gel.

5.6. Analytical date:-

5.6.1 Tert-butyl ((2S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(phenylthio)tetrahydro-2H-pyran-3-yl)carbamate (4)

Yield: 90% (591.2 mg) as a white foam. ¹H NMR (500 MHz, CDCl₃) δ = 7.55–7.52 (m, 2H), 7.30 (dt, *J* = 15.9, 6.4 Hz, 14H), 7.23 – 7.20 (m, 4H), 4.97 (d, *J* = 9.7 Hz, 1H), 4.80 (d, *J* = 10.8 Hz, 2H), 4.71 (d, *J* = 10.9 Hz, 2H), 4.59 (dd, *J* = 11.5, 5.2 Hz, 2H), 4.52 (d, *J* = 12.0 Hz, 1H), 3.93 (t, *J* = 8.4 Hz, 1H), 3.78 (dd, *J* = 10.8, 1.4 Hz, 1H), 3.72 (dd, *J* = 10.9, 4.4 Hz, 1H), 3.59 (dd, *J* = 16.7, 8.2 Hz, 2H), 3.35 (d, *J* = 8.8 Hz, 1H), 1.47 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ = 155.0, 138.3, 138.1, 133.2, 132.4, 128.8, 128.4, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 127.5, 127.5, 86.1, 82.7, 79.8, 79.2, 78.4, 75.2,

74.7, 73.4, 69.1, 56.3, 28.4, 27.8, 27.6, 14.17. HRMS: Calc. for C₃₈H₄₃NO₆S [M+Na]⁺: 664.2709, Obser. 664.2749.

5.6.2 (2S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(phenylthio)tetrahydro-2H-pyran-3-amine (5)

Yield: 90% (531.73 mg) as a pale yellow viscous. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.61– 7.41 (m, 2H), 7.30 – 7.24 (m, 5H), 7.24 – 7.17 (m, 8H), 7.17 – 7.13 (m, 5H), 4.87 (d, *J* = 11.2 Hz, 1H), 4.70 (d, *J* = 10.9 Hz, 1H), 4.65 (dd, *J* = 11.2, 2.0 Hz, 1H), 4.60 – 4.52 (m, 2H), 4.51 – 4.42 (m, 2H), 3.76 – 3.66 (m, 2H), 3.58 (td, *J* = 9.6, 1.9 Hz, 1H), 3.52 – 3.40 (m, 2H), 2.79 (td, *J* = 9.7, 2.0 Hz, 1H), 2.69 – 2.56 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ = 138.4, 138.2, 138.0, 133.0, 131.9, 129.0, 128.7, 128.5, 128.4, 128.1, 128.0, 128.0, 128.0, 127.9, 127.7, 127.7, 88.1, 86.0, 79.5, 78.4, 75.6, 74.9, 73.5, 69.0, 55.4. HRMS: Calc. for C₃₃H₃₆NO₄S [M+H]⁺: 542.2365, Obser. 542.2370.

5.6.3 (2S,3R,4R,5S,6R)-N-benzyl-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(phenylthio)tetrahydro-2H-pyran-3-amine (6)

Yield: 65% (416.0 mg) as viscous. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.50–7.47 (m, 2H), 7.28 – 7.21 (m, 9H), 7.16 (m, *J* = 14.7, 11.7, 4.8 Hz, 14H), 4.86 (d, *J* = 11.1 Hz, 1H), 4.76 (dd, *J* = 23.0, 10.9 Hz, 2H), 4.53 (d, *J* = 10.8 Hz, 3H), 4.47 (d, *J* = 11.9 Hz, 1H), 3.83 (s, 2H), 3.69 (dd, *J* = 19.3, 7.5 Hz, 2H), 3.65 – 3.42 (m, 4H), 2.72 (t, *J* = 9.3 Hz, 1H). ¹³**C NMR** (125 MHz, CDCl₃) δ = 140.4, 138.4, 138.3, 138.1, 133.5, 132.1, 128.9, 128.6, 128.59, 128.5, 128.4, 128.4, 128.0, 128.0, 127.9, 127.9, 127.8, 127.6, 127.63, 127.1, 88.4, 86.1, 79.4, 78.7, 75.5, 75.0, 73.5, 69.2, 62.3, 53.5. HRMS: Calc. for C₄₀H₄₂NO₄S [M+H]⁺ : 632.2865, Obser. 632.2870.

5.6.4 *N*-benzyl-N-((2S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(phenylthio)tetrahydro-2H-pyran-3-yl)nitrous amide (1a)

Yield: 75% (475.88 mg) as a pale yellow solid. Melting point 123.0 °C ¹H NMR (500 MHz, CDCl₃) δ 7.32 (dd, J = 8.1, 1.3 Hz, 2H), 7.27 – 7.19 (m, 10H), 7.18 – 7.06 (m, 11H), 6.97 (dd, J = 6.6, 2.9 Hz, 2H), 4.99 (d, J = 10.3 Hz, 1H), 4.80 (d, J = 14.5 Hz, 1H), 4.69 (d, J = 10.8 Hz, 1H), 4.65 (s, 1H), 4.62 (d, J = 3.4 Hz, 1H), 4.53 (dd, J = 11.4, 5.6 Hz, 2H), 4.46 (d, J = 11.9 Hz, 1H), 4.21 (dd, J = 18.3, 10.2 Hz, 2H), 3.99 (t, J = 10.0 Hz, 1H), 3.73 – 3.66 (m, 3H), 3.53 (m, J = 9.9, 4.0, 2.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.04, 137.84, 137.65, 133.78, 133.57, 131.92, 128.97, 128.85, 128.55, 128.45, 128.40, 128.21, 128.01, 127.94, 127.92, 127.86, 127.77, 127.59, 87.46, 79.78, 78.67, 77.35, 77.09, 76.84, 75.62, 75.15, 73.56, 71.71, 68.29, 66.70, 48.82. HRMS: Calc. for C₄₀H₄₀N₂O₅S [M+H]⁺: 661.2736, Obser. 661.2738.

5.6.5 Synthesis of thio-2-*N*-benzyl-*N*-Nitroso-3, 4, 6-tri-*O*-benzyl-2-deoxy-β-D-galactopyranoside (1b)

Yield: 65% (468.8 mg) as a pale yellow liquid. ¹H NMR (500 MHz, CDCl₃) δ 7.34 – 7.31 (m, 2H), 7.26 – 7.19 (m, 12H), 7.13 – 6.98 (m, 11H), 4.99 (d, *J* = 10.1 Hz, 1H), 4.71 (d, *J* = 11.1 Hz, 1H), 4.47 – 4.30 (m, 7H), 4.18 – 4.09 (m, 2H), 3.98 (s, 1H), 3.68 – 3.57 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 138.34, 137.72, 137.04, 133.12, 131.53, 129.87, 128.95, 128.43, 128.36, 128.29, 128.18, 127.93, 127.92, 127.86, 127.80, 127.76, 127.59, 127.48, 88.134, 77.52, 74.58, 73.60, 72.46, 72.14, 68.44, 61.73. HRMS: Calc. for C₄₀H₄₀N₂O₅S [M+H]⁺: 661.2736, Obser. 661.2728.

5.6.6 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2butoxytetrahydro-2H-pyran-3-yl)nitrous amide (3a)

Yield: 75% (70.91mg) as a white foam. ¹H NMR (500 MHz, CDCl₃) δ 7.38 – 7.28 (m, 10H), 7.28 – 7.15 (m, 8H), 7.09 – 7.02 (m, 2H), 5.16 (d, *J* = 14.5 Hz, 1H), 4.82 – 4.74 (m, 3H), 4.67 (d, *J* = 12.2 Hz, 1H), 4.60 – 4.56 (m, 2H), 4.51 (d, *J* = 14.5 Hz, 1H), 4.45 – 4.39 (m, 2H), 3.95 – 3.86 (m, 2H), 3.76 (dd, *J* = 18.5, 6.1 Hz, 3H), 3.61 (dt, *J* = 9.8, 3.0 Hz, 1H), 3.34 (dt, *J* = 9.2, 6.8 Hz, 1H), 1.52 – 1.45 (m, 2H), 1.28 (dd, *J* = 15.0, 7.6 Hz, 2H), 0.90 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 137.89, 137.71, 137.65, 133.75, 129.07, 128.45, 128.43, 128.37, 128.27, 127.84, 127.80, 127.77, 127.69, 127.65, 102.78, 82.17, 79.17, 75.41, 74.97, 74.95, 73.52, 69.85, 68.41, 67.59, 51.00, 31.41, 19.04, 13.77. HRMS: Calc. for C₃₈H₄₄N₂O₆ [M+H]⁺: 625.3278, Obser. 625.3281.

5.6.7 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(heptyloxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3b)

Yield: 80% (80.73mg) as a white foam. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.36 – 7.25 (m, 11H), 7.21 – 7.12 (m, 7H), 7.05 – 7.01 (m, 2H), 5.15 (d, *J* = 14.5 Hz, 1H), 4.79 – 4.71 (m, 3H), 4.64 (d, *J* = 12.2 Hz, 1H), 4.57 – 4.53 (m, 2H), 4.47 (d, *J* = 14.5 Hz, 1H), 4.42 – 4.36 (m, 2H), 3.92 – 3.82 (m, 2H), 3.76 – 3.70 (m, 3H), 3.58 (dt, *J* = 9.9, 3.1 Hz, 1H), 3.31 (dt, *J* = 9.3, 6.8 Hz, 1H), 1.50 – 1.44 (m, 2H), 1.26 (m, *J* = 25.9, 15.6, 8.1 Hz, 8H), 0.88 (t, *J* = 7.1 Hz, 3H). ¹³**C NMR** (125 MHz, CDCl₃) δ 137.89, 137.71, 137.65, 133.76, 129.04, 128.45, 128.42, 128.37, 128.27, 127.84, 127.80, 127.77, 127.69, 127.65, 127.64, 102.80, 82.12, 79.17, 75.40, 74.97, 74.94, 73.53, 70.19, 68.42, 67.57, 50.97, 31.71, 29.37, 28.97, 25.82, 22.57, 14.07. HRMS: Calc. for C₄₁H₅₀N₂O₆ [M+H]⁺: 667.3747, Obser. 667.3747.

5.6.8 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(isopentyloxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3c)

Yield: 76% (73.47mg) as a white foam. ¹H NMR (500 MHz, CDCl₃) δ = 7.37–7.25 (m, 11H), 7.21 – 7.13 (m, 7H), 7.06 – 7.01 (m, 2H), 5.12 (d, *J* = 14.5 Hz, 1H), 4.79 – 4.71 (m, 3H), 4.64 (d, *J* = 12.2 Hz, 1H), 4.58 – 4.53 (m, 2H), 4.48 (d, *J* = 14.5 Hz, 1H), 4.42 – 4.36 (m, 2H), 3.89 (dt, *J* = 9.2, 5.0 Hz, 2H), 3.77 – 3.70 (m, 3H), 3.58 (dt, *J* = 9.9, 3.0 Hz, 1H), 3.33 (dt, *J* = 9.3, 7.0 Hz, 1H), 1.55 (dt, *J* = 13.5, 6.7 Hz, 1H), 1.36 (dt, *J* = 7.8, 3.9 Hz, 2H), 0.85 (dd, *J* = 7.9, 6.7 Hz, 6H). ¹³C NMR (125MHz, CDCl₃) δ = 137.8, 137.7, 137.6, 133.7, 129.0, 128.4, 128.4, 128.3, 128.2, 127.8, 127.8, 127.8, 127.7, 127.6, 127.6, 102.7, 82.1, 79.1, 76.7, 75.3, 74.9, 74.9, 73.5, 68.4, 68.4, 67.5, 50.9, 38.0, 24.7, 22.5, 22.3. HRMS: Calc. for C₃₉H₄₆N₂O₆ [M+H]⁺: 639.3434, Obser. 639.3453.

5.6.9 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2isopropoxytetrahydro-2H-pyran-3-yl)nitrous amide (3d)

Yield: 78% (72.09 mg) as brown viscous. ¹H NMR (500 MHz, CDCl₃) δ = 7.35 – 7.31 (m, 4H), 7.30 – 7.25 (m, 6H), 7.24 (s, 1H), 7.21 – 7.13 (m, 7H), 7.04 – 7.00 (m, 2H), 5.04 (d, *J* = 14.4 Hz, 1H), 4.83 (d, *J* = 8.2 Hz, 1H), 4.78 (d, *J* = 10.8 Hz, 1H), 4.73 (d, *J* = 10.8 Hz, 1H), 4.64 – 4.54 (m, 4H), 4.39 (dt, *J* = 10.5, 4.2 Hz, 2H), 3.91 – 3.83 (m, 2H), 3.76 – 3.68 (m, 3H), 3.61 – 3.56 (m, 1H), 1.18 (d, *J* = 6.2 Hz, 3H), 0.97 (d, *J* = 6.1 Hz, 3H). ¹³C NMR (125MHz, CDCl₃) δ = 137.9, 137.7, 137.6, 133.7, 129.2, 128.4, 128.4, 128.3, 128.2, 127.8, 127.8, 127.7, 127.6, 101.3, 82.5, 79.1, 75.4, 74.9, 73.4, 72.4, 68.5, 67.8, 51.5, 23.3, 21.6. HRMS: Calc. for C₃₇H₄₂N₂O₆ [M+H]⁺: 611.3121, Obser. 611.3114.

5.6.10 *N*-benzyl-*N*-((2S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(tert-butoxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3e)

Yield: 80% (75.64 mg) as viscous yellow;¹**H NMR** (500 MHz, CDCl₃) δ = 7.36 – 7.29 (m, 8H), 7.28 – 7.17 (m, 10H), 7.04 (dd, J = 6.6, 2.9 Hz, 2H), 5.09 (d, J = 14.2 Hz, 1H), 4.98 (d, J = 8.2 Hz, 1H), 4.77 (dd, J = 31.5, 10.8 Hz, 2H), 4.65 – 4.55 (m, 4H), 4.47 – 4.39 (m, 2H), 3.89 (dd, J = 10.5, 8.2 Hz, 1H), 3.77 – 3.67 (m, 3H), 3.64 – 3.60 (m, 1H), 1.16 (s, 9H). ¹³**C NMR** (125 MHz, CDCl₃) δ = 138.0, 137.8, 137.6, 133.6, 129.4, 128.5, 128.4, 128.3, 128.2, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 97.6, 82.9, 79.2, 75.5, 74.8, 74.7, 73.4, 68.7, 68.0, 51.8, 28.4. HRMS: Calc. for C₃₈H₄₄N₂O₆ [M+H]⁺: 625.3278, Obser. 625.3276.

5.6.11 *N*-Benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(cyclohexyloxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3f)

Yield: 80% (78.79 mg) as a white foam. ¹**H NMR** (500 MHz, CDCl₃) δ 7.39 – 7.29 (m, 9H), 7.28 – 7.16 (m, 9H), 7.07 – 7.02 (m, 2H), 5.15 (d, *J* = 14.4 Hz, 1H), 4.90 (d, *J* = 8.2 Hz, 1H), 4.78 (dd, *J* = 25.3, 10.8 Hz, 2H), 4.66 (d, *J* = 12.2 Hz, 1H), 4.61 – 4.55 (m, 3H), 4.42 (dt, *J* = 10.5, 4.3 Hz, 2H), 3.90 (dd, *J* = 10.6, 8.3 Hz, 1H), 3.80 – 3.70 (m, 3H), 3.64 – 3.58 (m, 2H), 1.96 – 1.89 (m, 1H), 1.73 – 1.67 (m, 2H), 1.54 – 1.48 (m, 1H), 1.42 – 1.11 (m, 6H). ¹³**C NMR** (125 MHz, CDCl₃) δ = 137.9, 137.7, 137.6, 133.7, 129.2, 128.4, 128.4, 128.3, 128.2, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 101.1, 82.5, 79.2, 77.7, 76.7, 75.4, 74.9, 73.4, 68.5, 67.7, 33.3, 31.4, 25.4, 23.8, 23.6. HRMS: Calc. for C₄₀H₄₆N₂O₆ [M+H]⁺: 651.3434, Obser. 651.3433.

5.6.12 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3g)

Yield: 70% (74.88 mg) as a yellow foam. ¹**H NMR** (500 MHz, CDCl₃) $\delta = 7.35 - 7.26$ (m, 10H), 7.25 - 7.14 (m, 8H), 7.04 (dd, J = 6.5, 2.9 Hz, 2H), 4.97 (d, J = 14.4 Hz, 1H), 4.84 (d, J = 8.2 Hz, 1H), 4.76 (dd, J = 19.1, 10.9 Hz, 2H), 4.64 - 4.54 (m, 4H), 4.43 -4.37 (m, 2H), 3.83 - 3.69 (m, 4H), 3.57 - 3.53 (m, 1H), 3.42 (td, J = 10.6, 4.2 Hz, 1H), 2.22 - 2.15 (m, 1H), 1.74 (d, J = 12.1 Hz, 1H), 1.59 (dd, J = 9.1, 6.8 Hz, 2H), 1.27 (d, J =14.9 Hz, 2H), 1.08 - 0.91 (m, 3H), 0.86 (dd, J = 14.4, 6.8 Hz, 6H), 0.78 (d, J = 6.9 Hz, 3H), 0.57 - 0.50 (m, 1H). ¹³**C NMR** (125 MHz, CDCl₃) $\delta = 138.0$, 137.8, 137.8, 133.7, 129.3, 128.4, 128.3, 128.2, 127.9, 127.8, 127.6, 127.6, 127.6, 127.5, 99.7, 82.6, 79.2, 77.4, 76.7, 75.3, 74.9, 74.9, 73.7, 68.7, 67.7, 51.5, 47.7, 39.8, 34.2, 31.2, 25.1, 23.0, 22.1, 20.9, 15.8. HRMS: Calc. for C₄₄H₅₄N₂O₆ [M+H]⁺: 707.4060, Obser. 707.4064.

5.6.13 *N*-((2S,3R,4R,5S,6R)-2-(((3R,5R,7R)-adamantan-1-yl)oxy)-4,5-bis(benzyloxy)6-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)-N-benzylnitrous amide (3h)

Yield: 64% (68.07 mg) as viscous yellow. ¹H NMR (500 MHz, CDCl₃) δ = 7.29 (m, J = 12.4, 9.7, 6.2 Hz, 9H), 7.25 – 7.15 (m, 9H), 7.08 – 6.96 (m, 2H), 5.09 (dd, J = 24.2, 11.2 Hz, 2H), 4.78 (d, J = 10.9 Hz, 1H), 4.71 (d, J = 10.8 Hz, 1H), 4.64 – 4.52 (m, 4H), 4.45 – 4.34 (m, 2H), 3.90 – 3.83 (m, 1H), 3.76 – 3.59 (m, 4H), 2.11 – 2.04 (m, 3H), 1.71 (d, J = 11.4 Hz, 3H), 1.61 – 1.51 (m, 9H).¹³C NMR (125 MHz, CDCl₃) δ = 138.08, 137.79, 137.67, 133.70, 129.44, 128.50, 128.40, 128.30, 128.24, 127.80, 127.78, 127.76, 127.70, 127.65, 127.62, 127.56, 96.07, 82.89, 79.35, 77.25, 77.00, 76.75, 76.00, 75.50, 74.88,

74.72, 73.38, 68.92, 68.04, 51.94, 42.21, 36.02, 30.51. HRMS: Calc. for C₄₄H₅₀N₂O₆ [M+H]⁺: 703.3747, Obser. 703.3745.

5.6.14 *N*-benzyl-N-((2R,3R,4R,5S,6R)-2,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)nitrous amide (3i)

Yield: 70% (69.78 mg) as a pale yellow foam. ¹H NMR (500 MHz, CDCl₃) δ = 7.37 – 7.26 (m, 13H), 7.23 – 6.99 (m, 12H), 5.08 (d, J = 14.5 Hz, 1H), 4.86 (dd, J = 9.9, 5.7 Hz, 2H), 4.77 (d, J = 10.8 Hz, 1H), 4.72 (d, J = 10.9 Hz, 1H), 4.65 (d, J = 12.2 Hz, 1H), 4.56 (d, J = 11.5 Hz, 2H), 4.48 (dd, J = 16.4, 13.1 Hz, 2H), 4.41 – 4.34 (m, 2H), 3.97 (dd, J = 10.5, 8.3 Hz, 1H), 3.76 (dd, J = 14.2, 6.0 Hz, 3H), 3.62 – 3.57 (m, 1H). ¹³C NMR (125 MHz, CDCl₃) δ = 137.8, 137.7, 137.6, 136.5, 133.6, 129.0, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 127.9, 127.9, 127.8, 127.7, 127.7, 127.6, 127.6, 126.9, 101.7, 82.2, 79.1, 75.4, 75.0, 74.9, 73.5, 71.3, 68.3, 67.4, 65.3, 50.9. HRMS: Calc. for C₄₄H₅₀N₂O₆ [M+H]⁺: 703.3747, Obser. 703.3745. . HRMS: Calc. for C₄₁H₄₂N₂O₆ [M+H]⁺: 659.3121, Obser. 659.3119.

5.6.15 *N*-Benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-((2-chlorobenzyl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3j)

Yield: 72% (75.53 mg) as brown syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.34 (m, J = 14.3, 9.8, 5.0 Hz, 10H), 7.27–7.10 (m, 12H), 7.09–7.04 (m, 2H), 5.09 (d, J = 14.5 Hz, 1H), 4.93 (dd, J = 15.3, 10.4 Hz, 2H), 4.83–4.74 (m, 2H), 4.68 (d, J = 12.2 Hz, 1H), 4.62–4.51 (m, 4H), 4.45 – 4.37 (m, 2H), 4.04 (dd, J = 10.3, 8.4 Hz, 1H), 3.85–3.74 (m, 3H), 3.64 (dt, J = 9.8, 2.8 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 137.85, 137.72, 137.60, 134.48, 133.71, 133.08, 129.44, 129.25, 129.12, 129.06, 128.46, 128.44, 128.40, 128.30,

127.86, 127.80, 127.79, 127.73, 127.71, 127.67, 126.77, 101.91, 82.20, 79.05, 75.41, 75.11, 74.95, 73.58, 68.43, 68.27, 67.37, 50.77. HRMS: Calc. for C₄₁H₄₁ClN₂O₆ [M+H]⁺: 693.2731, Obser. 693.2734.

5.6.16 *N*-benzyl-N-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-((4-methylbenzyl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3k)

Yield: 77% (78.40 mg) as a pale yellow foam. ¹H NMR (500 MHz, CDCl₃) δ = 7.37 – 7.26 (m, 10H), 7.23 – 6.99 (m, 15H), 5.13 (d, *J* = 14.5 Hz, 1H), 4.84 – 4.64 (m, 5H), 4.56 (dd, *J* = 11.5, 3.3 Hz, 2H), 4.47 – 4.42 (m, 2H), 4.38 (dt, *J* = 9.0, 4.2 Hz, 2H), 3.95 (dd, *J* = 10.5, 8.3 Hz, 1H), 3.79 – 3.72 (m, 3H), 3.58 (dt, *J* = 9.9, 3.0 Hz, 1H), 2.34 (d, *J* = 5.5 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 137.9, 137.7, 137.7, 137.6, 133.6, 133.4, 129.0, 129.0, 128.4, 128.4, 128.4, 128.2, 128.0, 127.8, 127.7, 127.7, 127.6, 127.6, 101.6, 82.1, 79.1, 75.4, 75.0, 74.9, 73.5, 71.1, 68.3, 67.5, 51.0, 21.1. HRMS: Calc. for C₄₂H₄₄N₂O₆ [M+H]⁺: 673.3278, Obser. 673.3283.

5.6.17 *N*-benzyl-N-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-((4-methoxybenzyl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3l)

Yield: 70% (72.97 mg) as brown syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.37 – 7.26 (m, 9H), 7.24 (d, J = 3.5 Hz, 2H), 7.17 – 7.07 (m, 9H), 7.04 – 7.00 (m, 2H), 6.85 – 6.81 (m, 2H), 5.10 (d, J = 14.5 Hz, 1H), 4.83 – 4.76 (m, 3H), 4.71 (d, J = 10.9 Hz, 1H), 4.66 (d, J = 12.2 Hz, 1H), 4.56 (dd, J = 11.5, 4.0 Hz, 2H), 4.47 – 4.35 (m, 4H), 3.94 (dd, J = 10.5, 8.3 Hz, 1H), 3.80 (d, J = 4.0 Hz, 3H), 3.78 (t, J = 4.2 Hz, 2H), 3.74 (t, J = 6.7 Hz, 1H), 3.58 (dd, J = 8.0, 5.1 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ = 159.3, 137.8, 137.7, 137.6, 133.6, 129.6, 129.0, 128.6, 128.4, 128.4, 128.4, 128.2, 127.8, 127.7, 127.7, 127.6,

127.6, 113.7, 101.5, 82.1, 79.1, 75.4, 75.0, 74.9, 73.5, 71.0, 68.4, 67.5, 55.2, 51.0. . HRMS: Calc. for $C_{42}H_{44}N_2O_7[M+H]^+$: 689.3227, Obser. 689.3263.

5.6.18 *N*-benzyl-N-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-((4-fluorobenzyl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3m)

Yield: 68% (69.64 mg) as a white foam. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.38 – 7.23 (m, 13H), 7.22 – 7.11 (m, 5H), 7.09 – 6.93 (m, 6H), 4.98 (d, *J* = 14.5 Hz, 1H), 4.85 (d, *J* = 8.3 Hz, 1H), 4.82 – 4.71 (m, 3H), 4.64 (d, *J* = 12.2 Hz, 1H), 4.59 – 4.52 (m, 3H), 4.42 – 4.31 (m, 3H), 3.96 (dd, *J* = 10.4, 8.4 Hz, 1H), 3.76 (dd, *J* = 10.7, 6.4 Hz, 3H), 3.59 (dt, *J* = 9.9, 3.0 Hz, 1H). ¹³**C NMR** (125 MHz, CDCl₃) δ = 163.3, 161.4, 137.8, 137.6, 137.5, 133.5, 132.4, 132.3, 129.7, 129.6, 129.0, 128.4, 128.4, 128.3, 127.8, 127.8, 127.7, 127.7, 127.7, 127.6, 115.3, 115.1, 101.6, 82.4, 79.0, 75.4, 75.0, 74.9, 73.5, 70.5, 68.3, 67.4, 50.9. HRMS: Calc. for C₄₁H₄₁FN₂O₆ [M+H]⁺: 677.3027, Obser. 677.3026.

5.6.19 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-((4-cyanobenzyl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3n)

Yield: 70% (72.43 mg) as pale yellow syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.55 (d, J = 8.3 Hz, 2H), 7.35 – 7.26 (m, 11H), 7.22 – 7.05 (m, 11H), 4.90 – 4.53 (m, 9H), 4.36 (m, J = 19.4, 10.7, 6.4 Hz, 3H), 4.02 (dd, J = 10.5, 8.3 Hz, 1H), 3.88 – 3.73 (m, 3H), 3.59 (dt, J = 9.9, 3.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 142.2, 137.6, 137.5, 137.4, 133.6, 132.1, 129.1, 128.4, 128.4, 128.4, 127.9, 127.8, 127.8, 127.8, 127.8, 127.7, 118.7, 111.4, 101.7, 82.7, 78.9, 75.5, 75.1, 75.0, 73.5, 70.1, 68.2, 67.4, 50.8. HRMS: Calc. for C₄₂H₄₁N₃O₆ [M+H]⁺: 684.3074, Obser. 684.3071.

5.6.20 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(((8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3yl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (30)

Yield: 65% (92.20 mg) as a light yellow foam. ¹H NMR (500 MHz, CDCl₃) δ 7.37 – 7.28 (m, 10H), 7.27 – 7.16 (m, 8H), 7.06 (dd, J = 6.3, 3.0 Hz, 2H), 5.30 (d, J = 4.9 Hz, 1H), 4.97 (d, J = 14.4 Hz, 1H), 4.89 (d, J = 8.2 Hz, 1H), 4.81 – 4.55 (m, 6H), 4.44 – 4.37 (m, 2H), 3.89 (dd, J = 10.4, 8.3 Hz, 1H), 3.79 – 3.70 (m, 3H), 3.62 – 3.56 (m, 1H), 3.50 – 3.43 (m, 1H), 2.04 – 1.81 (m, 7H), 1.55 – 1.27 (m, 13H), 1.10 – 0.87 (m, 20H), 0.69 (s, 3H).¹³C NMR (125 MHz, CDCl₃) $\delta = 139.9$, 139.7, 137.9, 137.7, 137.6, 133.7, 129.3, 128.4, 128.4, 128.3, 128.3, 127.8, 127.7, 127.6, 127.6, 122.2, 56.7, 56.1, 51.5, 50.0, 42.2, 39.7, 39.4, 38.3, 37.1, 36.5, 36.1, 35.7, 31.8, 31.7, 29.4, 28.2, 28.0, 24.2, 23.7, 22.8, 22.5, 21.0, 19.3, 18.6, 11.8. HRMS: Calc. for C₆₁H₈₀N₂O₆ [M+H]⁺: 937.6095, Obser. 937.6087.

5.6.21 N-benzyl-N-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(((2R,3R,5R,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-

yl)methoxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3p)

Yield: 70% (107.54 mg) as a pale yellow syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.29 – 7.19 (m, 23H), 7.17 – 7.16 (m, 3H), 7.10 – 7.02 (m, 7H), 6.92 (dd, *J* = 6.6, 2.9 Hz, 2H), 5.08 (d, *J* = 14.3 Hz, 1H), 4.89 (d, *J* = 10.9 Hz, 1H), 4.74 – 4.60 (m, 7H), 4.56 (d, *J* = 17.9 Hz, 1H), 4.50 (dd, *J* = 8.2, 4.7 Hz, 2H), 4.47 (d, *J* = 3.0 Hz, 1H), 4.44 (d, *J* = 1.6 Hz, 1H), 4.28 (dt, *J* = 8.8, 4.2 Hz, 2H), 4.21 (d, *J* = 11.0 Hz, 1H), 4.00 (dd, *J* = 10.9, 2.0 Hz, 1H), 3.89 – 3.84 (m, 2H), 3.67 – 3.60 (m, 4H), 3.49 (ddd, *J* = 15.8, 8.8, 4.1 Hz, 2H), 3.36 (dd, *J* = 9.7, 3.5 Hz, 1H), 3.26 (s, 3H), 3.13 – 3.09 (m, 1H). ¹³C NMR (125 MHz, CDCl₃)

δ 138.7, 138.1, 138.0, 137.9, 137.7, 137.5, 133.6, 129.1, 128.6, 128.4, 128.4, 128.3, 128.3, 128.2, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.7, 127.6, 127.6, 127.5, 102.9, 98.0, 82.5, 81.8, 79.4, 79.1, 77.7, 75.7, 75.4, 75.2, 74.9, 74.8, 73.5, 73.2, 69.6, 68.5, 68.4, 67.3, 55.3, 51.2. HRMS: Calc. for C₆₂H₆₆N₂O₁₁ [M+Na]⁺: 1037.4564, Obser. 1037.4569.

5.6.22 (2S,3R,5R,6R)-6-((((2R,3R,4R,5S,6R)-3-(benzyl(nitroso)amino)-4,5bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-5-(benzyloxy)-2-methoxytetrahydro-2H-pyran-3,4-diyl dibenzoate (3q)

Yield: 70% (110.50 mg) as yellow syrup. ¹**H** NMR (500 MHz, CDCl₃) $\delta = 8.00$ (d, J = 8.2 Hz, 3H), 7.54 – 7.51 (m, 2H), 7.42 – 7.29 (m, 20H), 7.24 – 7.15 (m, 8H), 7.11 (dd, J = 6.6, 2.8 Hz, 2H), 6.02 (t, J = 9.3 Hz, 1H), 5.13 – 5.09 (m, 2H), 4.97 (dd, J = 21.5, 11.2 Hz, 2H), 4.85 – 4.78 (m, 3H), 4.70 – 4.61 (m, 3H), 4.46 (d, J = 10.9 Hz, 2H), 4.40 – 4.31 (m, 2H), 4.15 (dd, J = 11.2, 1.8 Hz, 1H), 4.06 (dd, J = 10.5, 8.3 Hz, 1H), 3.96 – 3.92 (m, 1H), 3.83 (d, J = 3.2 Hz, 2H), 3.79 (d, J = 9.2 Hz, 1H), 3.72 (dd, J = 11.2, 4.1 Hz, 1H), 3.66 – 3.62 (m, 1H), 3.56 (t, J = 9.6 Hz, 1H), 3.38 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.0, 165.6, 137.9, 137.7, 137.5, 137.5, 133.7, 133.2, 133.0, 129.9, 129.7, 129.5, 129.3, 129.1, 128.6, 128.4, 128.3, 128.3, 128.3, 128.2, 128.0, 127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 102.8, 96.9, 83.2, 79.1, 76.1, 75.5, 75.3, 74.9, 74.6, 73.5, 72.6, 72.1, 69.6, 68.5, 68.1, 67.5. HRMS: Calc. for C₆₂H₆₂N₂O₁₃ [M+Na]⁺: 1065.4150, Obser. 1065.4155.

5.6.23 *N*-benzyl-*N*-((2S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(((2R,3R,5R,6S)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-methoxytetrahydro-2Hpyran-3-yl)oxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3r)

Yield: 62% (95.25 mg) as yellow syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.32 – 7.18 (m, 20H), 7.17 – 7.04 (m, 15H), 5.39 (d, J = 8.1 Hz, 1H), 5.04 (d, J = 14.3 Hz, 1H), 4.79 – 4.71 (m, 3H), 4.65 – 4.50 (m, 5H), 4.45 – 4.34 (m, 5H), 4.26 – 4.18 (m, 2H), 4.02 (d, J = 12.0 Hz, 1H), 3.78 (dt, J = 18.7, 9.0 Hz, 2H), 3.70 (s, 1H), 3.67 – 3.46 (m, 5H), 3.34 – 3.20 (m, 2H), 3.12 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 138.6, 138.2, 138.1, 138.0, 137.8, 137.8, 134.1, 129.3, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.7, 127.5, 127.3, 127.3, 101.5, 97.4, 82.9, 81.3, 79.5, 76.0, 75.5, 74.9, 74.7, 73.8, 73.5, 73.3, 69.4, 68.6, 68.4, 54.9, 51.3. HRMS: Calc. for C₆₂H₆₆N₂O₁₁ [M+H]⁺: 1015.4745, Obser. 1015.4748.

5.6.24 (2S,3R,5R,6R)-5-(((2S,3R,4R,5S,6R)-3-(benzyl(nitroso)amino)-4,5bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-6-((benzyloxy)methyl)-2-methoxytetrahydro-2H-pyran-3,4-diyl dibenzoate (3s)

Yield: 65% (102.61 mg) as yellow syrup. ¹H NMR (500 MHz, CDCl₃) δ 7.90 (m, J = 19.8, 8.1, 1.0 Hz, 3H), 7.45 – 7.37 (m, 2H), 7.32 – 7.12 (m, 28H), 6.99 – 6.97 (m, 1H), 6.95 – 6.93 (m, 1H), 5.69 (dd, J = 29.5, 19.7 Hz, 1H), 5.10 – 4.98 (m, 2H), 4.76 – 4.47 (m, 6H), 4.41 – 4.26 (m, 3H), 4.25 – 4.08 (m, 4H), 3.63 (dd, J = 10.6, 8.2 Hz, 1H), 3.45 – 3.39 (m, 1H), 3.39 – 3.20 (m, 7H), 3.20 – 3.07 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 165.9, 165.8, 138.0, 137.7, 137.6, 133.5, 133.1, 132.6, 130.3, 129.8, 129.8, 129.7, 129.2, 128.4, 128.4, 128.3, 128.2, 128.1, 127.8, 127.8, 127.7, 127.6, 127.6, 127.5, 101.1, 96.9, 82.6, 79.4, 75.4, 74.8, 74.6, 73.1, 72.8, 72.7, 72.0, 70.7, 69.4, 68.7, 68.4, 67.6, 55.3, 52.2. HRMS: Calc. for C₆₂H₆₂N₂O₁₃ [M+H]⁺: 1043.4330, Obser. 1043.4333.

5.6.25 *N*-benzyl-*N*-((2S,3R,4R,5S,6R)-4,5-bis(benzyloxy)-2-(((4aR,6S,7R,8aR)-8-(benzyloxy)-6-methoxy-2-phenylhexahydropyrano[3,2-d][1,3]dioxin-7-yl)oxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)nitrous amide (3t)

Yield: 80% (162.0 mg) as yellow syrup. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.38 – 7.33 (m, 2H), 7.29 – 7.21 (m, 7H), 7.21 – 7.11 (m, 12H), 7.11 – 6.97 (m, 7H), 6.96 – 6.85 (m, 2H), 5.44 (s, 1H), 5.25 (d, *J* = 14.6 Hz, 1H), 5.01 (d, *J* = 8.2 Hz, 1H), 4.79 (d, *J* = 3.6 Hz, 1H), 4.62 (dd, *J* = 19.5, 10.8 Hz, 3H), 4.51 – 4.39 (m, 3H), 4.32 (m, *J* = 16.7, 15.4, 9.2 Hz, 4H), 4.21 (dd, *J* = 10.2, 4.8 Hz, 1H), 3.90 – 3.71 (m, 4H), 3.68 – 3.55 (m, 4H), 3.47 (m, *J* = 14.2, 11.7, 5.5 Hz, 2H), 3.33 (s, 3H). ¹³**C NMR** (125 MHz, CDCl₃) δ = 138.3, 137.9, 137.9, 137.8, 137.3, 133.9, 129.4, 129.0, 128.5, 128.4, 128.3, 128.3, 127.9, 127.9, 127.9, 127.9, 127.7, 127.6, 126.1, 103.6, 101.5, 100.3, 83.0, 81.7, 79.2, 77.8, 77.6, 75.4, 75.0, 74.9, 74.8, 73.5, 69.2, 68.5, 67.4, 62.2, 55.4, 51.1. HRMS: Calc. for C₅₅H₅₈N₂O₁₁ [M+Na]⁺: 945.3938, Obser. 945.3948.

5.6.26 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(((2R,3R,4S,5S,6S)-3,4,5-tris(benzyloxy)-6-methoxytetrahydro-2H-pyran-2-

yl)methoxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3u)

Yield: 75% (115.22 mg) as yellow syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.32 (d, J = 7.4 Hz, 8H), 7.29 – 7.20 (m, 18H), 7.14 – 7.05 (m, 7H), 6.97 – 6.92 (m, 2H), 5.57 (d, J = 14.6 Hz, 1H), 4.89 (d, J = 11.1 Hz, 1H), 4.76 – 4.66 (m, 6H), 4.64 – 4.57 (m, 4H), 4.54 – 4.50 (m, 2H), 4.45 (d, J = 1.7 Hz, 1H), 4.38 (t, J = 10.0 Hz, 2H), 4.18 (dd, J = 25.0, 12.4 Hz, 2H), 3.93 – 3.85 (m, 2H), 3.74 (dd, J = 11.9, 6.3 Hz, 4H), 3.69 – 3.48 (m, 4H), 3.27 – 3.24 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 138.5, 138.4, 138.2, 138.2, 138.0, 137.8, 133.8, 129.1, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.0, 127.9, 127.8,

127.8, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 127.5, 103.6, 99.1, 81.3, 80.1, 79.2, 75.4, 75.1, 75.0, 74.9, 74.9, 74.6, 73.5, 72.9, 72.1, 71.3, 68.7, 68.5, 67.3, 54.9, 50.9. HRMS: Calc. for C₆₂H₆₆N₂O₁₁ [M+H]⁺: 1015.4745, Obser. 1015.4751.

5.6.27 (2R,3R,4S,5S,6S)-2-((((2R,3R,4R,5S,6R)-3-(benzyl(nitroso)amino)-4,5bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-6methoxytetrahydro-2H-pyran-3,4,5-triyl tribenzoate (3v)

Yield: 70% (111.98 mg) as yellow syrup. ¹H NMR (500 MHz, CDCl₃) δ = 7.99 – 7.72 (m, 6H), 7.47 – 7.23 (m, 8H), 7.21 – 7.01 (m, 19H), 6.88 (dd, J = 6.6, 2.6 Hz, 2H), 5.80 (dd, J = 10.1, 3.4 Hz, 1H), 5.69 – 5.43 (m, 3H), 4.89 (d, J = 1.3 Hz, 1H), 4.72 – 4.54 (m, 3H), 4.46 (dd, J = 19.0, 11.5 Hz, 2H), 4.40 – 4.32 (m, 2H), 4.28 (d, J = 10.8 Hz, 1H), 4.22 – 4.11 (m, 2H), 4.01 (dd, J = 11.0, 1.9 Hz, 1H), 3.87 (dd, J = 10.5, 8.3 Hz, 1H), 3.62 (td, J = 8.8, 4.3 Hz, 4H), 3.49 – 3.44 (m, 1H), 3.39 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ = 165.7, 165.6, 165.5, 137.95, 137.8, 134.0, 133.5, 133.2, 129.9, 129.9, 129.8, 129.4, 129.1, 129.0, 128.6, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 127.9, 127.9, 127.8, 127.8, 127.8, 127.6, 103.3, 98.6, 81.2, 79.1, 77.4, 75.4, 75.1, 75.0, 73.6, 70.7, 70.0, 69.9, 68.9, 68.3, 67.6, 67.4, 55.7, 50.7. HRMS: Calc. for C₆₂H₆₀N₂O₁₄ [M+H]⁺: 1057.4123, Obser. 1057.4112.

5.6.28 *N*-benzyl-*N*-((2R,3R,4R,5S,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-((2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5yl)methoxy)tetrahydro-2H-pyran-3-yl)nitrous amide (3w)

Yield: 60% (73.63 mg) as brown syrup. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.28 – 7.19 (m, 9H), 7.17 (s, 2H), 7.14 – 7.02 (m, 7H), 6.98 (dd, *J* = 6.6, 2.8 Hz, 2H), 5.54 – 5.34 (m,

2H), 4.68 (dd, J = 9.7, 4.1 Hz, 3H), 4.56 (d, J = 12.2 Hz, 1H), 4.51 – 4.41 (m, 4H), 4.37 (d, J = 10.8 Hz, 1H), 4.30 (d, J = 14.9 Hz, 1H), 4.22 (dd, J = 5.1, 2.4 Hz, 1H), 4.07 – 3.96 (m, 2H), 3.85 (dd, J = 4.8, 1.9 Hz, 1H), 3.78 (dd, J = 10.6, 8.3 Hz, 1H), 3.70 – 3.58 (m, 3H), 3.50 (m, J = 10.5, 6.1, 3.1 Hz, 2H), 1.46 (s, 3H), 1.35 (d, J = 3.6 Hz, 3H), 1.25 (t, J = 8.2 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) $\delta = 138.0$, 137.9, 137.9, 134.4, 129.3, 128.5, 128.5, 128.3, 128.1, 127.9, 127.9, 127.8, 127.7, 127.6, 109.5, 108.6, 103.9, 96.4, 81.4, 79.2, 75.5, 75.0, 75.0, 73.7, 71.3, 70.9, 70.4, 69.8, 68.4, 67.2, 66.9, 50.6, 26.2, 26.0, 25.0, 24.5. HRMS: Calc. for C₄₆H₅₄N₂O₁₁ [M+H]⁺: 811.3806, Obser. 811.3814.

5.6.29 (2R,3R,5R,6S)-2-((((2R,3R,4R,5S,6R)-3-(benzyl(nitroso)amino)-4,5bis(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)-6methoxytetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate) (3x)

Yield: 80% (120.72 mg) as yellow syrup. ¹**H NMR** (500 MHz, CDCl₃) δ = 7.30–7.01 (m, 18H), 6.93 (dd, J = 6.5, 3.0 Hz, 2H), 5.48 (dd, J = 19.4, 9.9 Hz, 1H), 5.24 (t, J = 12.4 Hz, 1H), 4.87 – 4.79 (m, 2H), 4.74 – 4.59 (m, 4H), 4.54 (d, J = 12.1 Hz, 1H), 4.49 – 4.41 (m, 2H), 4.30 (dt, J = 25.0, 13.6 Hz, 3H), 3.90 (m, J = 19.0, 9.5, 7.0 Hz, 2H), 3.76 – 3.59 (m, 4H), 3.51 – 3.40 (m, 2H), 3.25 (d, J = 10.1 Hz, 3H), 1.22 – 1.16 (m, 2H), 1.13 – 1.09 (m, 6H), 1.07 (s, 8H), 1.06 – 1.01 (m, 11H). ¹³C NMR (125 MHz, CDCl₃) δ = 177.7, 177.0, 176.8, 137.9, 137.8, 137.8, 133.9, 129.1, 128.6, 128.5, 128.3, 127.9, 127.8, 127.8, 127.8, 127.7, 103.1, 96.6, 81.7, 79.1, 75.4, 75.1, 75.0, 73.7, 71.2, 69.6, 68.7, 68.6, 68.5, 68.4, 67.3, 55.8, 50.6, 38.8, 38.8, 27.2, 27.1, 27.0. HRMS: Calc. for C₅₆H₇₂N₂O₁₄ [M+H]⁺: 997.5062, Obser. 997.5070.


5.6.30 *N*-benzyl-N-((2R,3R,4R,5R,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(cyclohexyloxy)tetrahydro-2H-pyran-3-yl)nitrous amide (4a)

Yield: 72% (70.25 mg) as a yellow foam. ¹H NMR (500 MHz, CDCl₃) δ 7.30 – 7.18 (m, 10H), 7.18 – 7.07 (m, 8H), 7.00 (dd, J = 6.5, 3.1 Hz, 2H), 5.18 (d, J = 14.5 Hz, 1H), 4.79 (d, J = 7.8 Hz, 1H), 4.71 (d, J = 11.3 Hz, 1H), 4.49 – 4.37 (m, 5H), 4.33 – 4.14 (m, 3H), 3.96 (d, J = 1.1 Hz, 1H), 3.66 – 3.44 (m, 4H), 1.60 – 1.51 (m, 3H), 1.38 (d, J = 5.2 Hz, 1H), 1.30 – 1.21 (m, 2H), 1.16 – 1.00 (m, 4H). ¹³C NMR (125 MHz, CDCl₃) δ 138.3, 137.8, 137.3, 133.8, 129.2, 128.4, 128.3, 128.2, 128.1, 127.8, 127.8, 127.7, 127.6, 127.6, 127.4, 101.5, 80.8, 77.5, 74.6, 73.6, 73.5, 72.3, 68.6, 64.3, 51.7, 33.3, 31.3, 25.4, 23.8, 23.6. HRMS: Calc. for C₄₀H₄₆N₂O₆ [M+H]⁺: 651.3434, Obser. 651.3428.


5.6.31 *N*-benzyl-N-((2R,3R,4R,5R,6R)-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(isopentyloxy)tetrahydro-2H-pyran-3-yl)nitrous amide (4b)

Yield: 77% (74.2 mg) as yellow syrup. ¹**H NMR** (500 MHz, CDCl₃) δ 7.29 – 7.18 (m, 10H), 7.13 – 7.00 (m, 10H), 5.17 (d, J = 14.6 Hz, 1H), 4.68 (dd, J = 28.9, 9.6 Hz, 2H), 4.42 (m, J = 20.4, 14.7, 5.7 Hz, 5H), 4.27 – 4.16 (m, 3H), 3.97 (d, J = 1.5 Hz, 1H), 3.80 – 3.76 (m, 1H), 3.59 (m, J = 15.8, 8.3, 4.6 Hz, 3H), 3.25 (dd, J = 16.4, 7.2 Hz, 1H), 1.46 (dt, J = 13.5, 6.7 Hz, 1H), 1.31 – 1.24 (m, 2H), 0.75 (dd, J = 8.4, 6.7 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 138.2, 137.7, 137.2, 133.8, 129.0, 128.4, 128.3, 128.2, 128.2, 128.1, 127.8, 127.7, 127.6, 127.5, 127.4, 103.2, 80.5, 74.6, 73.6, 73.5, 72.2, 68.4, 64.1, 51.3, 38.0, 24.7, 22.6, 22.3. HRMS: Calc. for C₃₉H₄₆N₂O₆ [M+H]⁺: 639.3434, Obser. 639.3430.

5.7. Spectra few compounds.



7,328 7,7328 7,7282 7,7282 7,7282 7,7282 7,7282 7,7282 7,7282 7,7282 7,7282 7,7282 7,7284 7,7294 7,7



100 90 f1 (ppm) 80 70

60

50

40

30

20

10

Department of Chemistry, IIT (BHU), Varanasi.

150

140

130

120 110


160

200

190

180 170

ò








Figure 5.7 ¹³C NMR Spectra of product 3t in CDCl₃




Figure 5.8 COSY NMR Spectra of product 3c in CDCl₃




Figure 5.9 HSQC NMR Spectra of product 3c in CDCl₃

5.8 References

- (a) R. N. Loeppky and J. R. Outram, "N-Nitroso Compounds: Occurrence and Biological Effects," IARC Scientific Publishers, Lyon, 1982; (b) R. N. Loeppky and C. J. Michejda, "Nitrosamines and Related N-Nitroso Compounds: Chemistry and Biochemistry," ACS Symposium Series, American Chemical Society, Washington, DC, 1994.
- (a) P. G. Wang, T. B. Cai and N. Taniguchi, "Nitric Oxide Donor, For Pharmaceutical and Biological Applications," WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2005; (b) P. G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai, & A. J. Janczuk, "Nitric oxide donors: chemical activities and biological applications," *Chemical reviews*, **102**(2002) 1091-1134.
- 3. (a) H. Kakeya, M. Imoto, Y. Takahashi, H. Naganawa, T. Takeuchi, & K. Umezawa, "Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces II. structure determination," The Journal of antibiotics, 46(1993) 1716-1719. (b) M. Li, Shandilya, M. A. Carpenter, A. Rathore, W. L. Brown, A. L. Perkins, & R. S. Harris, "First-in-class small molecule inhibitors of the singlestrand DNA cytosine deaminase APOBEC3G," ACS chemical biology, 7(2012) 506-517.(c) R. Sen, "Principles and Management of Cancer," B I Publications Pvt Ltd, New Delhi, 2004. (d) C. T. Gnewuch, & G. Sosnovsky, "A critical appraisal anticancer drugs," Chemical evolution of *N*-nitrosoureas of the as Reviews, 97(1997) 829-1014. (e) A. A. Rossini, A. A. Like, W. L. Chick, M. C. Appel, & G. F. Cahill Jr, "Studies of streptozotocin-induced insulitis and diabetes," Proceedings of the National Academy of Sciences, 74(1977) 2485-2489. (f) H. Iinuma, T. TAKEUCHI, S. KONDO, M. MATSUZAKI, H. UMEZAWA, & M. OHNO, "Dopastin, an inhibitor of dopamine β-hydroxylase," The Journal of Antibiotics, 25(1972) 497-500.
- 4. (a) J.-P. Anselme, "N-Nitrosamines," ACS Symposium Series, American Chemical Society, 1979. (b) J. E. Saavedra, "Recent synthetic applications of Nnitrosamines and related compounds," Organic Preparations and Procedures International, 19(1987) 83-159. (c) I. D. Entwistle, R. A. Johnstone, & A. H. Wilby, "Metal-assisted reactions-Part 11: Rapid reduction of N-nitrosamines to N, N-disubstituted hydrazines; the utility of some low-valent titanium reagents," Tetrahedron, 38(1982) 419-423. (d) F. W. Schueler, & C. Hanna, "A Curarimimetic Analog of Decamethylene Ditrimethylammonium (C10)," Journal of the American Chemical Society, 74(1952) 2112-2113. (e) W. W. Hartman, & L. J. Roll, "a-Methyl-a-phenylhydrazine," Org. Synth., 13(1933) 66-67. (f) R. L. Hinman, & K. L. HAMM, "Synthesis of Some 1, 1-Dibenzylhydrazines1," The Journal of Organic Chemistry, 23(1958) 529-531. (g) D. L. Browne, & J. P. Harrity, "Recent developments in the chemistry of sydnones," Tetrahedron, 66(2010) 553-568. (h) F. H. C. Stewart, "The chemistry

of the sydnones," *Chemical Reviews*, **64**(1964) 129-147. (i) D. L. H. Williams, "The mechanism of the Fischer-Hepp rearrangement of aromatic *N*-nitrosoamines," *Tetrahedron*, **31**(1975) 1343-1349. (j) I. Cikotiene, M. Jonusis, & V. Jakubkiene, "The first example of the Fischer–Hepp type rearrangement in pyrimidines," *Beilstein journal of organic chemistry*, **9**(2013) 1819-1825. (k) D. Seebach, & D. Enders, "Umpolung of amine reactivity. Nucleophilic α -(secondary amino)-alkylation via metalated nitrosamines," *Angewandte Chemie International Edition in English*, **14**(1975) 15-32.

- 5. (a) R. H. Crabtree & A. Lei, "Introduction: CH activation," *Chemical Reviews*, 117(2017) 8481-8482. (b) N. Kuhl, M. N. Hopkinson, J. Wencel-Delord & F. Glorius, "Beyond Directing Groups: Transition-Metal-Catalyzed C□ H Activation of Simple Arenes," *Angewandte Chemie International Edition*, 51(2012) 10236-10254.
- 6. (a) B. Liu, Y. Fan, Y. Gao, C. Sun, C. Xu, & J. Zhu, "Rhodium (III)-catalyzed Nnitroso-directed C-H olefination of arenes. High-yield, versatile coupling under mild conditions," Journal of the American Chemical Society, 135(2013) 468-473. (b) B. Liu, C. Song, C. Sun, S. Zhou, & J. Zhu, "Rhodium (III)-catalyzed indole synthesis using N-N bond as an internal oxidant," Journal of the American Chemical Society, 135(2013) 16625-16631. (c) C. Wang & Y. Huang, "Traceless directing strategy: efficient synthesis of N-alkyl indoles via redox-neutral C-H activation," Organic letters, 15(2013) 5294-5297. (d) J. Chen, P. Chen, C. Song, & J. Zhu, "Rhodium (III)-Catalyzed N-Nitroso-Directed C H Addition to Ethyl 2-Oxoacetate for Cycloaddition/Fragmentation of Synthesis Indazoles," Chemistry-A European Journal, 20(2014) 14245-14249. (e) T. Gao, & P. Sun, "Palladium-Catalyzed N-Nitroso-Directed C-H Alkoxylation of Arenes and Subsequent Formation of 2-Alkoxy-N-alkylarylamines," The Journal of Organic Chemistry, 79(2014) 9888-9893. (f) Y. Wu, L. J. Feng, X. Lu, F. Y. Kwong, & H. B. Luo, "Palladium-catalyzed oxidative C-H bond acylation of Nnitrosoanilines with toluene derivatives: a traceless approach to synthesize Nalkyl-2-aminobenzophenones" Chemical Communications, **50**(2014) 15352-15354. (g) F. Xie, Z. Qi, S. Yu, & X. Li, "Rh (III)-and Ir (III)-catalyzed C-H alkynylation of arenes under chelation assistance," Journal of the American Chemical Society, 136(2014) 4780-4787. (h) S. Yu, & X. Li, "Rhodium (III)catalyzed C-C coupling of arenes with 2-vinyloxiranes: synthesis of allylic alcohols," Organic letters, 16(2014) 1200-1203. (i) D. D. Li, Y. X. Cao, & G. W. Wang, "Palladium-catalyzed ortho-acyloxylation of N-nitrosoanilines via direct sp 2 C-H bond activation," Organic & Biomolecular Chemistry, 13(2015) 6958-6964.
- (a) A. Varki, "Essentials of Glycobiology," Cold Spring Harbor Laboratory Press, New York (USA), 1999.
 (b) T. K. Lindhorst, "Essentials of Carbohydrate Chemistry and Biochemistry," WILEY-VCH Verlag GmbH & Co. KGaA,

Weinheim, 2008. (c) P. H. Seeberger, & D. B. Werz, "Synthesis and medical applications of oligosaccharides," *Nature*, **446**(2007) 1046-1051. (d) P. H. Seeberger & D. B. Werz, "Automated synthesis of oligosaccharides as a basis for drug discovery," *Nature Reviews Drug Discovery*, **4**(2005) 751-763.

- (a) C. S. Bennett, "Selective Glycosylations: Synthetic Methods and Catalysts," Wiley-VCH Verlag GmbH & Co. KGaA, 2017. (b) D. B. Werz, S. Vidal, "Modern Synthetic Methods in Carbohydrate Chemistry: From Monosaccharides to Complex Glycoconjugates," Wiley-VCH Verlag GmbH & Co. KGaA, 2014. (c) S. H. Khan, "Modern Methods in Carbohydrate Synthesis," CRC Press, Taylor & Francis Group, 1996.
- 9. (a) K. H. Jung, M. Müller & R. R. Schmidt, "Intramolecular O-glycoside bond formation," Chemical Reviews, 100(2000) 4423-4442. (b) X. Zhu, & R. R. Schmidt, "New principles for glycoside-bond formation," Angewandte Chemie *International Edition*, **48**(2009) 1900-1934. (c) A. Demchenko. V. (Ed.). "Handbook of chemical glycosylation: advances in stereoselectivity and therapeutic relevance," John Wiley & Sons, (2008). (d) A. Ishiwata, Y. J. Lee & Y. Ito, "Recent advances in stereoselective glycosylation through intramolecular aglycon delivery," Organic & biomolecular chemistry, 8(2010) 3596-3608. (e) B. Schumann, S. G. Parameswarappa, M. P. Lisboa, N. Kottari, F. Guidetti, C. L. Pereira & P. H. Seeberger, "Nucleophile-Directed Stereocontrol Over Glycosylations Using Geminal-Difluorinated Nucleophiles," Angewandte Chemie International Edition, 55(2016) 14431-14434.
- 10. M. R. E. S. Aly & H. El Sayed, "Recent Advances Toward Robust N-Protecting Groups for Glucosamine as Required for Glycosylation Strategies," *Advances in carbohydrate chemistry and biochemistry*, **73**(2016) 117-224.
- (a) P. Chaudhary, S. Gupta, N. Muniyappan, S. Sabiah & J. Kandasamy, "An efficient synthesis of N-nitrosamines under solvent, metal and acid free conditions using tert-butyl nitrite," *Green Chemistry*, 18(2016) 2323-2330. (b) P. Chaudhary, S. Gupta, N. Muniyappan, S. Sabiah & J. Kandasamy, "Regioselective nitration of N-alkyl anilines using tert-butyl nitrite under mild condition," *The Journal of Organic Chemistry*, 84(2018) 104-119. (c) P. Chaudhary, S. Gupta, P. Sureshbabu, S. Sabiah & J. Kandasamy, "A metal free reduction of aryl-*N*-nitrosamines to the corresponding hydrazines using a sustainable reductant thiourea dioxide," *Green Chemistry*, 18(2016) 6215-6221. (d) P. Chaudhary, R. Korde, S. Gupta, P. Sureshbabu, S. Sabiah & J. Kandasamy, "An Efficient Metal-Free Method for the Denitrosation of Aryl N-Nitrosamines at Room Temperature," *Advanced Synthesis & Catalysis*, 360 (2018) 556-561. (e) P. Sureshbabu, S. Azeez, P. Chaudhary & J. Kandasamy, "tert-Butyl nitrite promoted transamidation of

secondary amides under metal and catalyst free conditions," *Organic & Biomolecular Chemistry*, **17**(2019) 845-850. f) S. Chauhan, P. Chaudhary, A. K. Singh, P. Verma, V. Srivastava, & J. Kandasamy, "tert-Butyl nitrite induced radical dimerization of primary thioamides and selenoamides at room temperature," *Tetrahedron letters*, **59** (2018) 272-276. g) S. Azeez, P. Chaudhary, P. Sureshbabu, S. Sabiah & J. Kandasamy, "tert-Butyl nitrite mediated nitrogen transfer reactions: synthesis of benzotriazoles and azides at room temperature," *Organic & Biomolecular Chemistry*, **16**(2018) 8280-8285.

- 12. (a) A. Kumar Singh, R. Venkatesh, V. Kumar Kanaujiya, V. Tiwari & J. Kandasamy, "Palladium-Catalyzed Reaction of Aryl Iodides and Glycal Enones: Application in the Preparation of Dapagliflozin Analogues," European Journal of Organic Chemistry, 2022(2022) e202200023. (b) A. K. Singh, V. K. Kanaujiya, V. Tiwari, S. Sabiah & J. Kandasamy, "Development of Routes for the Stereoselective Preparation of β -Aryl-C-glycosides via C-1 Aryl Enones," Organic letters, 22(2020) 7650-7655. (c) K. Bihari Mishra & J. Kandasamy, "Tris (Pentafluorophenyl) Borane-Driven stereoselective O-glycosylation with glycal donors under mild condition," Asian Journal of Organic Chemistry, 8(2019) 549-554. (d) A. K. Singh & J. Kandasamy, "Palladium catalyzed stereocontrolled synthesis of C-aryl glycosides using glycals and arenediazonium salts at room temperature," Organic & Biomolecular Chemistry, 16(2018) 5107-5112. (e) K. B. Mishra, A. K. Singh & J. Kandasamy, "Tris (pentafluorophenyl) borane-Promoted Stereoselective Glycosylation with Glycosyl Trichloroacetimidates under Mild Conditions," The Journal of Organic Chemistry, 83(2018) 4204-4212. (f) V. Tiwari, K. Murugan, S. Sabiah & J. Kandasamy," An efficient and direct esterification uronic acids of using H_2SO_4 -SiO₂ at room temperature," Tetrahedron Letters, 99(2022) 153852. (g) V. Tiwari, A. K. Singh, P. Chaudhary, P. H. Seeberger & J. Kandasamy, "Synthesis of photolabile protecting group (PPG) protected uronic acid building blocks: applications in carbohydrate synthesis with the assistance of a continuous flow photoreactor," Organic Chemistry Frontiers, 6(2019) 3859-3863. (h) V. Tiwari, V. N. Badavath, A. K. Singh & J. Kandasamy, "A highly efficient TEMPO mediated oxidation of sugar primary alcohols into uronic acids using 1-chloro-1, 2-benziodoxol-3 (1H)-one at room temperature," Tetrahedron Letters, 59(2018) 2511-2514.
- 13. R. Arihara, K. Kakita, N. Suzuki, S. Nakamura & S. Hashimoto, "Glycosylation with 2-acetamido-2-deoxyglycosyl donors at a low temperature: Scope of the non-oxazoline method," *The Journal of Organic Chemistry*, **80**(2015) 4259-4277.
- 14. Y. Singh, M. C. Rodriguez Benavente, M. H. Al-Huniti, D. Beckwith, R. Ayyalasomayajula, E. Patino & M. Cudic, "Positional scanning MUC1 glycopeptide library reveals the importance of PDTR epitope glycosylation for lectin binding," *The Journal of organic chemistry*, **85**(2019) 1434-1445.